







an Open Access Journal by MDPI

Chronic Lymphocytic Leukemia: New Insights and Future Directions

Guest Editor:

Dr. Mohamed Gadelkarim

Immunomodulation and Translational Cancer Research Program, Department of Surgery, School of Medicine, University of Missouri NextGen Precision Health Bldg., 1030 Hitt Street, Columbia, MO 65211, USA

Deadline for manuscript submissions:

closed (29 November 2023)

Message from the Guest Editor

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries.

The prognosis for CLL mainly depends on the presence or absence of specific genetic aberrations, which include del(11q), del(17p), TP53 dysfunction, and immunoglobulin heavy-chain gene mutations. Recently, published evidence elucidated targeting B-cell leukemia/lymphoma 2, Bruton's tyrosine kinase, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta, all which are considered promising and reliable targets for CLL treatment. However, these shreds of evidence elucidating favorable outcomes and prolonged progression-free survival in patients treated with these therapies are insufficient to reach robust conclusions and guidelines for treatment.

In this context, we aim to explore the epidemiology, microenvironment, gene mutations, and promising treatment targets for CLL in this Special Issue. The scope of the Special Issue is deliberately kept broad, which would allow coverage of a wide range of perspectives and different topics related to CLL pathogenesis and management, with particular emphasis on new insights and future directions.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed,

MEDLINE, PMC, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General

Medicine)

Contact Us